Developed platform targets cancerous lesions while avoiding healthy areas as much as possible
In a study published in the journal Biomaterials, researchers from the Technion Faculty of Biomedical Engineering in Haifa claim to have developed an automatic system for designing and preparing stabilizing materials to produce a “nano-sized box” – a platform for delivering drugs to cancer cells in the body. This innovation would have demonstrated its effectiveness on solid cancerous tumors during preclinical trials.
Unlike chemotherapy, which damages healthy tissue at the same time as cancer cells, causing significant side effects, the platform developed targets only cancerous lesions, avoiding healthy areas as much as possible.
The system developed at the Technion is used both as a “robot-chemist” which synthesizes new substances and as a “robot-pharmacist” which prepares nano capsules containing the anti-cancer drug.
“The technology we have developed is based on a phenomenon of light emission based on the aggregation state of the drug. However, when it is soluble or stable in a capsule, it emits almost no light”, explains director Dr Yossi Shamai of the laboratory in which the study was conducted.
The automatic system developed at the Technion makes it possible to know, according to the light energy emitted by the drug, which material creates the best nanoparticles for this drug.
The new material has an efficiency of 90% of the drug load and can predict the effectiveness of the treatment. The researchers found that the new nasal material is superior to other existing materials in various aspects, including efficacy, safety, uniformity of the particles that compose it, stability over time, and the number of drugs that can be ” wrapped” and stabilized.